MDGL
MADRIGAL PHARMACEUTICALS, INC.
+1.25 (+0.24%)530.35USD64.5K成交股數12.3B市值–本益比(近四季)9.5股價營收比+71.2%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 364M+71% | 311M+127% | 321M+416% | 287M+1862% | 213M | 137M | 62.2M | 14.6M | 0.00 | 0.00 | 0.00 | 0.00 |
| 營業成本 | – | – | – | – | – | 4.5M | – | – | 0.00 | – | – | – |
| 毛利 | – | – | – | – | – | 133M | – | – | 0.00 | – | – | – |
| 毛利率 | – | – | – | – | – | 96.7% | – | – | – | – | – | – |
| 研發費用 | 91.2M | 109M | 116M | 174M | 54.1M | 44.2M | 68.7M | 71.1M | 71.2M | 70.6M | 71.0M | 68.6M |
| 銷售管理費用 | 289M | 269M | 240M | 209M | 197M | 168M | 108M | 105M | 80.8M | 46.5M | 27.6M | 17.8M |
| 營業利益 | −56.3M+19% | −92.7M+17% | −59.6M-49% | −114M-30% | −47.2M-69% | −79.3M-32% | −116M+18% | −163M+88% | −152M | −117M | −98.5M | −86.5M |
| 營業利益率 | -15.5% | -29.8% | -18.6% | -39.7% | -22.2% | -57.8% | -187.1% | -1,110.4% | – | – | – | – |
| 稅後淨利 | −57.9M+37% | −94.4M+29% | −58.6M-45% | −114M-25% | −42.3M-71% | −73.2M-35% | −107M+8% | −152M+77% | −148M | −112M | −98.7M | −85.8M |
| 淨利率 | -15.9% | -30.3% | -18.2% | -39.8% | -19.9% | -53.4% | -172.0% | -1,038.2% | – | – | – | – |
| 稀釋 EPS | -1.99+33% | -3.25+25% | -2.03-59% | -4.01-44% | -1.50-80% | -2.61-54% | -4.92-8% | -7.10+51% | -7.38 | -5.68 | -5.34 | -4.69 |
| 稀釋股數 | 29.1M | 29.0M | 28.4M | 28.5M | 28.2M | 28.1M | 21.7M | 21.4M | 20.0M | 19.8M | 18.5M | 18.3M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 293M | 227M | 199M | 296M | 186M | 184M | 233M | 495M | 623M | 99.9M | 62.1M | 77.2M |
| 應收帳款 | 192M | 187M | 134M | 113M | 79.2M | 61.4M | 30.5M | 6.9M | – | 0.00 | – | – |
| 存貨 | 99.4M | 112M | 74.8M | 69.3M | 63.5M | 55.2M | 8.7M | 7.1M | 854K | 0.00 | – | – |
| 總資產 | 1.2B | 1.2B | 1.3B | 1.4B | 1.0B | 997M | 1.1B | 1.1B | 1.1B | 641M | 238M | 302M |
| 有息負債 | 341M | 340M | 340M | 340M | 118M | 118M | 117M | 117M | 116M | 115M | 115M | 99.2M |
| 總負債 | 721M | 684M | 657M | 737M | 319M | 286M | 296M | 243M | 232M | 235M | 216M | 199M |
| 股東權益 | 524M | 543M | 603M | 626M | 696M | 711M | 777M | 857M | 851M | 405M | 22.2M | 104M |
| 負債比 | 57.9% | 55.7% | 52.2% | 54.1% | 31.5% | 28.7% | 27.6% | 22.1% | 21.4% | 36.7% | 90.7% | 65.8% |
| 淨現金(現金 − 有息負債) | −48.1M | −113M | −141M | −44.1M | 67.8M | 65.6M | 116M | 378M | 506M | −15.6M | −52.7M | −22.1M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −167M+88% | – | – | – | −88.9M | – | – | −149M | – | – | – |
| 資本支出 | – | 3.8M | – | – | – | 0.00 | – | – | 357K | – | – | – |
| 自由現金流 | – | −171M+93% | – | – | – | −88.9M | – | – | −150M | – | – | – |
| 折舊攤銷 | – | 386K | – | – | – | 379K | – | – | 168K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -55.0% | – | – | – | -64.8% | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 958M | +432.1% | −288M | -30.1% | -10.15 | −190M |
| FY2024 | 180M | – | −466M | -258.6% | -17.31 | −457M |
| FY2023 | 0.00 | – | −374M | –% | -17.33 | −326M |
| FY2022 | 0.00 | – | −295M | –% | -17.23 | −225M |
| FY2021 | 0.00 | – | −242M | –% | -14.63 | −184M |
| FY2020 | 0.00 | – | −202M | –% | -13.09 | −158M |
| FY2019 | 0.00 | – | −83.9M | –% | -5.45 | −41.8M |
| FY2018 | 0.00 | – | −32.8M | –% | -2.22 | −25.5M |